γ-Aminobutyric acid (GABA) transporter 1 (GAT1)1 regulates neuronal excitation of the central nervous system by clearing the synaptic cleft of the inhibitory neurotransmitter GABA upon its release from synaptic vesicles. Elevating the levels of GABA in the synaptic cleft, by inhibiting GABA reuptake transporters, is an established strategy to treat neurological disorders, such as epilepsy2. Here we determined the cryo-electron microscopy structure of full-length, wild-type human GAT1 in complex with its clinically used inhibitor tiagabine3, with an ordered part of only 60 kDa. Our structure reveals that tiagabine locks GAT1 in the inward-open conformation, by blocking the intracellular gate of the GABA release pathway, and thus suppresses neurotransmitter uptake. Our results provide insights into the mixed-type inhibition of GAT1 by tiagabine, which is an important anticonvulsant medication. Its pharmacodynamic profile, confirmed by our experimental data, suggests initial binding of tiagabine to the substrate-binding site in the outward-open conformation, whereas our structure presents the drug stalling the transporter in the inward-open conformation, consistent with a two-step mechanism of inhibition4. The presented structure of GAT1 gives crucial insights into the biology and pharmacology of this important neurotransmitter transporter and provides blueprints for the rational design of neuromodulators, as well as moving the boundaries of what is considered possible in single-particle cryo-electron microscopy of challenging membrane proteins.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Guastella, J. et al. Cloning and expression of a rat brain GABA transporter. Science 249, 1303–1306 (1990).
Madsen, K. K., White, H. S. & Schousboe, A. Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol. Ther. 125, 394–401 (2010).
Braestrup, C. et al. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier. J. Neurochem. 54, 639–647 (1990).
Blat, Y. Non-competitive inhibition by active site binders. Chem. Biol. Drug Des. 75, 535–540 (2010).
Sieghart, W. Structure, pharmacology, and function of GABAA receptor rubtypes. GABA 54, 231–263 (2006).
Bowery, N. G. et al. International Union of Pharmacology. XXXIII. Mammalian γ-aminobutyric acidB receptors: structure and function. Pharmacol. Rev. 54, 247–264 (2002).
Fattorini, G., Melone, M. & Conti, F. A reappraisal of GAT-1 localization in neocortex. Front. Cell. Neurosci. 14, 9 (2020).
Roberts, B. M. et al. GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model. Nat. Commun. 11, 4958 (2020).
Mermer, F. et al. Common molecular mechanisms of SLC6A1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. Brain 144, 2499–2512 (2021).
Rosenthal, M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J. Clin. Psychiatry 64, 1245–1249 (2003).
Lyu, S. et al. Blockade of GABA transporter-1 and GABA transporter-3 in the lateral habenula improves depressive-like behaviors in a rat model of Parkinson’s disease. Neuropharmacology 181, 108369 (2020).
Fuhrer, T. E. et al. Impaired expression of GABA transporters in the human Alzheimer’s disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus. Neuroscience 351, 108–118 (2017).
Paparrigopoulos, T., Tzavellas, E., Karaiskos, D., Malitas, P. & Liappas, I. An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects. J. Psychopharmacol. 24, 1375–1380 (2010).
Schwartz, T. L. et al. An open-label study of tiagabine as augmentation therapy for anxiety. Ann. Clin. Psychiatry 17, 167–172 (2005).
Carpenter, L. L. et al. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J. Clin. Psychiatry 67, 66–71 (2006).
Kragholm, B. et al. Discovery of a subtype selective inhibitor of the human betaine/GABA transporter 1 (BGT-1) with a non-competitive pharmacological profile. Biochem. Pharmacol. 86, 521–528 (2013).
Hauke, T. J., Wein, T., Höfner, G. & Wanner, K. T. Novel allosteric ligands of γ-aminobutyric acid transporter 1 (GAT1) by MS based screening of pseudostatic hydrazone libraries. J. Med. Chem. 61, 10310–10332 (2018).
Jurik, A. et al. A binding mode hypothesis of tiagabine confirms liothyronine effect on γ-aminobutyric acid transporter 1 (GAT1). J. Med. Chem. 58, 2149–2158 (2015).
Zafar, S. & Jabeen, I. Molecular dynamic simulations to probe stereoselectivity of tiagabine binding with human GAT1. Molecules 25, 4745 (2020).
Skovstrup, S., David, L., Taboureau, O. & Jørgensen, F. S. A steered molecular dynamics study of binding and translocation processes in the GABA transporter. PLoS ONE 7, e39360 (2012).
Keynan, S., Suh, Y. J., Kanner, B. I. & Rudnick, G. Expression of a cloned gamma-aminobutyric acid transporter in mammalian cells. Biochemistry 31, 1974–1979 (1992).
Cammack, J. N., Rakhilin, S. V. & Schwartz, E. A. A GABA transporter operates asymmetrically and with variable stoichiometry. Neuron 13, 949–960 (1994).
Lester, H. A., Mager, S., Quick, M. W. & Corey, J. L. Permeation properties of neurotransmitter transporters. Annu. Rev. Pharmacol. Toxicol. 34, 219–249 (1994).
Jardetzky, O. Simple allosteric model for membrane pumps. Nature 211, 969–970 (1966).
Krishnamurthy, H. & Gouaux, E. X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. Nature 481, 469–474 (2012).
Penmatsa, A., Wang, K. H. & Gouaux, E. X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 503, 85–90 (2013).
Gotfryd, K. et al. X-ray structure of LeuT in an inward-facing occluded conformation reveals mechanism of substrate release. Nat. Commun. 11, 1005 (2020).
Singh, S. K., Yamashita, A. & Gouaux, E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 448, 952–956 (2007).
Coleman, J. A., Green, E. M. & Gouaux, E. X-ray structures and mechanism of the human serotonin transporter. Nature 532, 334–339 (2016).
Coleman, J. A. et al. Serotonin transporter–ibogaine complexes illuminate mechanisms of inhibition and transport. Nature 569, 141–145 (2019).
Shahsavar, A. et al. Structural insights into the inhibition of glycine reuptake. Nature 591, 677–681 (2021).
Zhou, Z. et al. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 317, 1390–1393 (2007).
Kantcheva, A. K. et al. Chloride binding site of neurotransmitter sodium symporters. Proc. Natl Acad. Sci. USA 110, 8489–8494 (2013).
Li, F. et al. Ion transport and regulation in a synaptic vesicle glutamate transporter. Science 368, 893–897 (2020).
Zimmermann, I. et al. Synthetic single domain antibodies for the conformational trapping of membrane proteins. eLife 7, e34317 (2018).
Tsutsumi, N. et al. Structure of human Frizzled5 by fiducial-assisted cryo-EM supports a heterodimeric mechanism of canonical Wnt signaling. eLife 9, e58464 (2020).
Wu, X. & Rapoport, T. A. Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies). Proc. Natl Acad. Sci. USA 118, e2115001118 (2021).
Borden, L. A. et al. Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur. J. Pharmacol. 269, 219–224 (1994).
Suzdak, P. D., Foged, C. & Andersen, K. E. Quantitative autoradiographic characterization of the binding of [3H]tiagabine (NNC 05-328) to the GABA uptake carrier. Brain Res. 647, 231–241 (1994).
Korkhov, V. M., Farhan, H., Freissmuth, M. & Sitte, H. H. Oligomerization of the γ-aminobutyric acid transporter-1 is driven by an interplay of polar and hydrophobic interactions in transmembrane helix II. J. Biol. Chem. 279, 55728–55736 (2004).
White, H. S. et al. Correlation between anticonvulsant activity and inhibitory action on glial gamma-aminobutyric acid uptake of the highly selective mouse gamma-aminobutyric acid transporter 1 inhibitor 3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole and its N-alkylated analogs. J. Pharmacol. Exp. Ther. 302, 636–644 (2002).
Malinauskaite, L. et al. A mechanism for intracellular release of Na+ by neurotransmitter/sodium symporters. Nat. Struct. Mol. Biol. 21, 1006–1012 (2014).
Ben-Yona, A. & Kanner, B. I. Functional defects in the external and internal thin gates of the γ-aminobutyric acid (GABA) transporter GAT-1 can compensate each other. J. Biol. Chem. 288, 4549–4556 (2013).
Bismuth, Y., Kavanaugh, M. P. & Kanner, B. I. Tyrosine 140 of the gamma-aminobutyric acid transporter GAT-1 plays a critical role in neurotransmitter recognition. J. Biol. Chem. 272, 16096–16102 (1997).
Dhar, T. G. et al. Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3. J. Med. Chem. 37, 2334–2342 (1994).
Kanner, B. I. Transmembrane domain I of the gamma-aminobutyric acid transporter GAT-1 plays a crucial role in the transition between cation leak and transport modes. J. Biol. Chem. 278, 3705–3712 (2003).
Rudnick, G. Forty four years with Baruch Kanner and the chloride ion. Neurochem. Res. 47, 3–8 (2022).
Wang, K. H., Penmatsa, A. & Gouaux, E. Neurotransmitter and psychostimulant recognition by the dopamine transporter. Nature 521, 322–327 (2015).
Bulling, S. et al. The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. J. Biol. Chem. 287, 18524–18534 (2012).
Alberati, D. et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 62, 1152–1161 (2012).
Wang, X., Ratnaraj, N. & Patsalos, P. N. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus). Seizure 13, 574–581 (2004).
Sandtner, W. et al. Binding mode selection determines the action of ecstasy homologs at monoamine transporters. Mol. Pharmacol. 89, 165–175 (2016).
Clausen, R. P. et al. Structure–activity relationship and pharmacology of gamma-aminobutyric acid (GABA) transport inhibitors. Adv. Pharmacol. 54, 265–284 (2006).
Reith, M. E. A. et al. Novel C-1 substituted cocaine analogs unlike cocaine or benztropine. J. Pharmacol. Exp. Ther. 343, 413–425 (2012).
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
Alexandrov, A. I., Mileni, M., Chien, E. Y. T., Hanson, M. A. & Stevens, R. C. Microscale fluorescent thermal stability assay for membrane proteins. Structure 16, 351–359 (2008).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214–1221 (2020).
Bordoli, L. et al. Protein structure homology modeling using SWISS-MODEL workspace. Nat. Protoc. 4, 1–13 (2009).
Goddard, T. D., Huang, C. C. & Ferrin, T. E. Visualizing density maps with UCSF Chimera. J. Struct. Biol. 157, 281–287 (2007).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D60, 2126–2132 (2004).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010).
Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D74, 531–544 (2018).
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12–21 (2010).
Abraham, M. J. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1–2, 19–25 (2015).
Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 29, 1859–1865 (2008).
Kim, S. et al. CHARMM-GUI ligand reader and modeler for CHARMM force field generation of small molecules. J. Comput. Chem. 38, 1879–1886 (2017).
Leonard, A. N. & Lyman, E. Activation of G-protein-coupled receptors is thermodynamically linked to lipid solvation. Biophys. J. 120, 1777–1787 (2021).
Lomize, M. A., Pogozheva, I. D., Joo, H., Mosberg, H. I. & Lomize, A. L. OPM database and PPM web server: resources for positioning of proteins in membranes. Nucleic Acids Res. 40, D370–D376 (2012).
McGibbon, R. T. et al. MDTraj: a modern open library for the analysis of molecular dynamics trajectories. Biophys. J. 109, 1528–1532 (2015).
DeLano, W. L. Pymol: an open-source molecular graphics tool. CCP4 http://legacy.ccp4.ac.uk/newsletters/newsletter40/11_pymol.html (2002).
Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018).
We thank K. Villers and C. Hanson for technical support for recombinant protein expression in mammalian and Sf9 cells; C. Cato and R. Oania for general laboratory support; S. Khan for helpful discussions; T. Osinski, J. Chu and B. D. Kim at the USC Center for Advanced Research Computing (CARC) for support with computing resources; and D. J. Slotboom (University of Groningen) and K. Pande (LBNL) for comments and suggestions on the manuscript. This research was supported by a US National Institutes of Health grant R35 GM127086 (to V.C.). We acknowledge the Center of Excellence for Nano Imaging (CNI) at the University of Southern California for microscope time.
The authors declare no competing interests.
Peer review information
Nature thanks Azadeh Shahsavar, Harald Sitte and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Fig. 1 Protein purification of GAT1 for cryo-EM analysis and [3H]-GABA uptake assay results for quantification of relative uptake rates.
a, Size-exclusion chromatography on a Superose 6 Increase (10/300) column shows a monodisperse peak at a size of approximately 100 kDa, accommodating the protein, as well as the LMNG/CHS detergent micelle. b, SDS-PAGE prior to cryo-EM sample preparation, confirms the high purity of the final sample (> 95%). For gel source data, see Supplementary Fig. 4. c, Thermal stability assay as described in the methods section. Changing the detergent from DDM to LMNG resulted in an increase of Tm by 12 °C. AU, arbitrary units. d, Scintillation proximity assay of GAT1 purified from Sf9 cells, showing specific competition of [3H]-GABA with tiagabine, presented as all data points, overlaid with a nonlinear regression fit, resulting in an IC50 of 290 ± 60 nM. The experiment was performed three times independently with similar results. e, Absolute counts of a representative [3H]-GABA uptake experiment from constructs used for probing tiagabine binding pocket. (Bottom) Comparison of expression levels, based on relative fluorescence of whole cells compared to wildtype GAT1, and maximum uptake values, relative to wildtype GAT1 in above experiment
Extended Data Fig. 2 Cryo-EM reconstruction of full-length, wild-type human GAT1 in complex with tiagabine.
a, Workflow of cryo-EM processing of GAT1 in complex with tiagabine in the inward-open conformation with representative micrograph, picking templates and 2D classes. Data processing was entirely performed in cryoSPARC57. After motion correction, CTF estimation and particle picking, the dataset was sorted using 2D classification, followed by 3D ab initio reconstruction and heterogenous refinement for further clean-up of the particle stack. Finally, 3D reconstructions were performed using non-uniform refinement58 and local refinement, which yielded a final map of 3.8 Å resolution. b, Data quality of the final reconstruction, illustrated as a local resolution map ranging from 3 - 4.8 Å, gold-standard fourier shell correlation plot (masked and unmasked) and angular sampling of the final reconstruction
Extended Data Fig. 3 Atomic model and cryo-EM Coulomb potential map of the human GAT1 complex with tiagabine.
The overall structure of the GAT1 (cyan) complex with bound tiagabine (salmon) (right) and magnified views of individual transmembrane helices (left) are shown in the cryo-EM map (grey mesh) at 5 sigma.
a, Sequence alignment of GABA transporters: human GAT1, GAT2, GAT3 (Uniprot: P30531, Q9NSD5, P48066). Green boxes highlight conserved residues observed in the substrate binding pocket and red boxes highlight non-conserved residues. b, AlphaFold55 prediction of GAT1 and GAT2 in the outward-open conformation with tiagabine superimposed with substrate from LeuT (PDB ID: 4HOD33), highlighting non-conserved residues between the two subtypes in the substrate-binding pocket. c, AlphaFold55 prediction of GAT1 outward-open conformation, superimposed with experimentally determined inward-open cryo-EM structure, shows the small relative transition that tiagabine bound to GAT1 would have to undergo for the proposed induced-fit mechanism.
a, Superposition of outward-open dDAT26 (PDB ID: 4XP1, yellow, residues F53, Y142, S320 in stick representation) with outward-open SERT30 (PDB ID: 6DZY, red, residues F105, Y121, S336 in stick representation). b, Superposition of outward-open dDAT26 (PDB ID: 4XP1, yellow, residues F53, Y142, S320 in stick representation) with inward-open GAT1 (this study, residues F70, Y86, S295 in stick representation). c, Superposition of inward-open GAT1 structure (this study, residues F70, Y86, S295 in stick representation) with inward-open GlyT131 (PDB ID: 6ZBV, blue, residues F126, Y142, S371 in stick representation). a–c are shown to confirm the conformational state (inward-open) of GAT1, together with the conformation of the Na+ and Cl− coordinating residues suggesting likely empty ion binding pockets. d–f, Superimposed structures of inward-open conformation SERT, GlyT1 and GAT1, highlighting differences in the relative orientation of TM1a. g,h, Superposition to GlyT1 and SERT, showing differences in extracellular gate. GlyT1 shows a very similar network of interactions to GAT1, while the inward-open SERT structure shows markedly larger distances between the corresponding residues. Numbers correspond to the shortest atomic distances, between the respective residues, in Å.
Extended Data Fig. 6 Structural comparison of GAT1 (green) with GlyT1 (blue) and SERT (pink) inward-open structures.
a, Superposition of overview models between three structures. b, Focus on the intracellular gate, showing differences in TM6b, TM7, TM1a and TM5. c–e, Minor differences between GAT1, GlyT1 and SERT in TM12, TM9, TM10 and TM8 with respective residues highlighted in stick representation: G457 highlights the unique residue in GAT1, potentially leading to additional flexibility of TM10. The interacting residues between ibogaine and SERT TM8 A441-G442-L443 show a subtle helix break, which is unique among the compared sequences and structures.
a, Time series showing the shortest observed distance among heavy atoms of the respective GAT1 residues to the 3-methyl-2-thienyl moiety of tiagabine. Numbers in parentheses are the mean and standard deviation of the respective distances in MD simulations. See Supplementary Figs. 1 and 2 for time series of individual trajectories and Supplementary Fig. 3 for histograms of these distances. b, Snapshots of tiagabine binding site for one of the trajectories, taken every 200 ns and spanning 1000 ns. Tiagabine from the cryo-EM structure is colored dark green, MD simulations light green, GAT1 cryo-EM structure in dark pink, GAT1 MD simulations in light pink. c, Root mean square fluctuations (r.m.s.f.) per residue in GAT1. Solid line shows the average of 10 independent trajectories at each residue position; shading refers to 95% confidence interval (n = 10). d, Root mean square deviation (r.m.s.d.) of GAT1 Cα in the 1 µs simulations. The r.m.s.d. are calculated with the protein in trajectories superimposed on the protein in the first frame. e, Root mean square deviation (r.m.s.d.) of tiagabine heavy atoms in the 1 µs simulations. The r.m.s.d. are calculated with the protein in trajectories superimposed on the protein in the first frame.
Blue circle highlights nipecotic acid moiety, sand colored circle highlights bis(3-methyl-2-thienyl) tail.
About this article
Cite this article
Motiwala, Z., Aduri, N.G., Shaye, H. et al. Structural basis of GABA reuptake inhibition. Nature 606, 820–826 (2022). https://doi.org/10.1038/s41586-022-04814-x